Zacks Gives Neutral Rating to Varian Medical Systems (VAR)
Varian Medical Systems (NYSE: VAR)‘s stock had its “neutral” rating reiterated by Zacks in a research note issued to investors on Monday. They currently have a $67.00 price target on the stock.
VAR has been the subject of a number of other recent research reports. Analysts at Citigroup (NYSE: C) cut their EPS estimates on shares of Varian Medical Systems in a research note on Thursday. They now have a “neutral” rating and a $67.00 price target on the stock. Separately, analysts at Needham & Company reiterated a “buy” rating on shares of Varian Medical Systems in a research note to investors on Thursday, April 26th. Finally, analysts at Caris & Co. upgraded shares of Varian Medical Systems from an “average” rating to a “buy” rating in a research note to investors on Monday, March 12nd.
Shares of Varian Medical Systems opened at 63.42 on Monday. Varian Medical Systems has a 52 week low of $48.72 and a 52 week high of $71.95. The company has a market cap of $7.128 billion and a P/E ratio of 18.50.
The company last announced its quarterly results on Wednesday, April 25th. It reported $0.96 earnings per share (EPS) for the previous quarter, meeting the Thomson Reuters consensus estimate of $0.96 EPS. The company’s quarterly revenue was up 11.1% on a year-over-year basis. Analysts expect that Varian Medical Systems will post $1.14 EPS next quarter.
Varian Medical Systems, Inc. is engaged in the design, manufacture, sale and service of equipment and software products for treating cancer with radiotherapy, stereotactic radiotherapy, stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and brachytherapy.